

Rohit Aggarwal

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1212150/rohit-aggarwal-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103
papers

4,310
citations

33
h-index

64
g-index

115
ext. papers

5,662
ext. citations

4.5
avg, IF

5.67
L-index

#	Paper	IF	Citations
103	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1955-1964	2.4	393
102	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. <i>Arthritis and Rheumatism</i> , 2013 , 65, 314-24		383
101	Distinctions between diagnostic and classification criteria?. <i>Arthritis Care and Research</i> , 2015 , 67, 891-7	4.7	268
100	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2271-2282	9.5	210
99	Methods of formal consensus in classification/diagnostic criteria and guideline development. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 95-105	5.3	204
98	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2582-91		182
97	Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 227-32	2.4	172
96	Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 740-9	9.5	167
95	Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. <i>Arthritis Care and Research</i> , 2016 , 68, 689-94	4.7	134
94	Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1472-83		133
93	Chemokines in multiple myeloma. <i>Experimental Hematology</i> , 2006 , 34, 1289-95	3.1	110
92	Anti-U3 RNP autoantibodies in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1112-8		102
91	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. <i>Journal of Rheumatology</i> , 2015 , 42, 2168-71	4.1	99
90	Approach to asymptomatic creatine kinase elevation. <i>Cleveland Clinic Journal of Medicine</i> , 2016 , 83, 37-42.8		74
89	Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. <i>Journal of Rheumatology</i> , 2017 , 44, 319-325	4.1	68
88	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , 2017 , 3, e000507	5.9	66
87	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 792-801	2.4	65

86	Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 55-62	2.4	61
85	Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2009 , 36, 1209-16	4.1	60
84	Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes--an Indian perspective. <i>Clinical Rheumatology</i> , 2009 , 28, 327-31	3.9	56
83	Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review. <i>Journal of Rheumatology</i> , 2018 , 45, 841-850	4.1	55
82	Update on outcome assessment in myositis. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 303-318	8.1	55
81	Treatment in myositis. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 279-289	8.1	54
80	Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. <i>Journal of Rheumatology</i> , 2009 , 36, 2711-4	4.1	54
79	Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. <i>Arthritis Care and Research</i> , 2011 , 63, 891-8	4.7	52
78	Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. <i>Rheumatology</i> , 2017 , 56, 247-254	3.9	51
77	Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. <i>Rheumatology</i> , 2016 , 55, 991-9	3.9	45
76	Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. <i>Rheumatology</i> , 2019 , 58, 1011-1015	3.9	45
75	A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome. <i>Journal of Rheumatology</i> , 2017 , 44, 223-229	4.1	43
74	Clinical characteristics of patients with ankylosing spondylitis in India. <i>Clinical Rheumatology</i> , 2009 , 28, 1199-205	3.9	43
73	Therapeutic advances in myositis. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 635-41	5.3	38
72	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017 , 69, 891-899	9.5	36
71	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017 , 69, 898-910	9.5	33
70	Biologic predictors of clinical improvement in rituximab-treated refractory myositis. <i>BMC Musculoskeletal Disorders</i> , 2015 , 16, 257	2.8	31
69	The use and abuse of diagnostic/classification criteria. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014 , 28, 921-34	5.3	31

68	Efficacy and safety of adrenocorticotrophic hormone gel in refractory dermatomyositis and polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 720-727	2.4	30
67	COVID-19 and Myositis: What We Know So Far. <i>Current Rheumatology Reports</i> , 2021 , 23, 63	4.9	29
66	Paraneoplastic myalgias and myositis. <i>Rheumatic Disease Clinics of North America</i> , 2011 , 37, 607-21	2.4	28
65	Anti-signal recognition particle autoantibody ELISA validation and clinical associations. <i>Rheumatology</i> , 2015 , 54, 1194-9	3.9	26
64	Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 317-325	4.5	26
63	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organization Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 788-794	2.4	24
62	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. <i>Rheumatology</i> , 2017 , 56, 1884-1893	3.9	23
61	Pulmonary pathologic manifestations of anti-glycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy. <i>Journal of Clinical Pathology</i> , 2014 , 67, 678-83	3.9	23
60	Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. <i>Journal of Rheumatology</i> , 2009 , 36, 914-7	4.1	23
59	Anti-MDA5 Antibody Spectrum in Western World. <i>Current Rheumatology Reports</i> , 2018 , 20, 78	4.9	22
58	Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 1265-75	5.1	20
57	The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 504-512	5.3	19
56	The pulmonary histopathologic manifestations of the anti-PL7/antithreonyl transfer RNA synthetase syndrome. <i>Human Pathology</i> , 2014 , 45, 1199-204	3.7	19
55	COVID-19 and myositis - unique challenges for patients. <i>Rheumatology</i> , 2021 , 60, 907-910	3.9	19
54	Therapeutic approaches in myositis. <i>Current Rheumatology Reports</i> , 2011 , 13, 182-91	4.9	17
53	Improvement in Herpes Zoster Vaccination in Patients with Rheumatoid Arthritis: A Quality Improvement Project. <i>Journal of Rheumatology</i> , 2017 , 44, 11-17	4.1	16
52	Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. <i>British Journal of Dermatology</i> , 2020 , 182, 410-417	4	16
51	The pulmonary histopathology of anti-KS transfer RNA synthetase syndrome. <i>Archives of Pathology and Laboratory Medicine</i> , 2015 , 139, 122-5	5	14

50	Immune-mediated statin myopathy. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 33-8	5.1	14
49	Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. <i>Clinical Reviews in Allergy and Immunology</i> , 2017 , 52, 81-87	12.3	12
48	Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation. <i>Rheumatology</i> , 2014 , 53, 433-7	3.9	12
47	Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 113-120	5.3	12
46	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021 , 60, 2615-2628	3.9	12
45	Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis. <i>Rheumatology</i> , 2017 , 56, 384-389	3.9	11
44	Risk Factors and Cancer Screening in Myositis. <i>Rheumatic Disease Clinics of North America</i> , 2020 , 46, 565-576	5.7	11
43	Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies. <i>Case Reports in Rheumatology</i> , 2016 , 2016, 9068061	0.8	11
42	Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study"). <i>Medicine (United States)</i> , 2021 , 100, e23677	1.8	10
41	Type I interferon and T helper 17 cells co-exist and co-regulate disease pathogenesis in lupus patients. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 646-53	2.3	9
40	Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level. <i>Scandinavian Journal of Rheumatology</i> , 2020 , 49, 405-411	1.9	9
39	Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 655-63	2.2	9
38	Antisynthetase syndrome: A distinct disease spectrum.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 178-191	2.3	7
37	COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. <i>Rheumatology International</i> , 2021 , 1	3.6	7
36	Idiopathic inflammatory myopathies. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 86	51.1	7
35	Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy. <i>Rheumatology</i> , 2021 , 60, 5713-5723	3.9	7
34	Refractory Cutaneous Dermatomyositis With Severe Scalp Pruritus Responsive to Apremilast. <i>Journal of Clinical Rheumatology</i> , 2019 ,	1.1	6
33	Biologics for idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2017 , 29, 645-651	5.3	5

32	Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathy. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4440-4455	15.9	5
31	Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1140-1149	5.3	5
30	Utility of patient-reported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 539-546	5.3	5
29	Tattoo reaction as a presenting manifestation of systemic sarcoidosis. <i>Rheumatology</i> , 2019 , 58, 927	3.9	5
28	Follow-up results of myositis patients treated with H. P. Acthar gel. <i>Rheumatology</i> , 2020 , 59, 2976-2981	3.9	4
27	Pulmonary Pathologic Manifestations of Anti-Alanyl-tRNA Synthetase (Anti-PL-12)-Related Inflammatory Myopathy. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 191-197	5	4
26	Inclusion body myositis: therapeutic approaches. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2012 , 2, 43-52	5.4	4
25	Improving Pneumococcal Vaccination Rates in Rheumatology Patients by Using Best Practice Alerts in the Electronic Health Records. <i>Journal of Rheumatology</i> , 2021 , 48, 1472-1479	4.1	4
24	Hand-held dynamometry for assessment of muscle strength in patients with inflammatory myopathies. <i>Rheumatology</i> , 2021 , 60, 2146-2156	3.9	4
23	Clinical trials and novel therapeutics in dermatomyositis. <i>Expert Opinion on Emerging Drugs</i> , 2020 , 25, 213-228	3.7	3
22	Histopathologic Findings in 5 Patients With Hypomyopathic Dermatomyositis: The Importance of MHC-1 Expression on Myofibers. <i>Journal of Clinical Neuromuscular Disease</i> , 2015 , 17, 52-8	1.1	3
21	Myositis in clinical practice-relevance of new antibodies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 887-901	5.3	2
20	Drs. Aggarwal and Oddis reply. <i>Journal of Rheumatology</i> , 2018 , 45, 446	4.1	1
19	Update on the treatment of myositis. <i>International Journal of Clinical Rheumatology</i> , 2014 , 9, 505-518	1.5	1
18	Validation of two simple patient-centered outcome measures for virtual monitoring of patients with idiopathic inflammatory myositis. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	1
17	Management Considerations: Pharmacologic Intervention 2020 , 275-283		1
16	B-Cell Targeted Therapies in Systemic Sclerosis and Inflammatory Myopathies. <i>Milestones in Drug Therapy</i> , 2014 , 153-180		1
15	Inclusion body myositis in the rheumatology clinic. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 1126-1135	2.3	1

14	Consumer-based activity trackers in evaluation of physical activity in myositis patients. <i>Rheumatology</i> , 2021 ,	3.9	1
13	Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. <i>Indian Journal of Rheumatology</i> , 2022 ,	0.5	1
12	Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211060907	2.8	0
11	High Prevalence of Active Tuberculosis in Adults and Children with Idiopathic Inflammatory Myositis as Compared with Systemic Lupus Erythematosus in a Tuberculosis Endemic Country: Retrospective Data Review from a Tertiary Care Centre in India. <i>Mediterranean Journal of Rheumatology</i> , 2021 , 32, 134-142	1.4	0
10	Systemic lupus erythematosus after Pfizer COVID-19 vaccine: a case report.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	0
9	Defining anti-synthetase syndrome: a systematic literature review.. <i>Clinical and Experimental Rheumatology</i> , 2022 , 40, 309-319	2.2	0
8	Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. <i>Rheumatology International</i> ,	3.6	0
7	Drs. Sheth and Aggarwal reply. <i>Journal of Rheumatology</i> , 2017 , 44, 961	4.1	
6	Drs. Aggarwal and Oddis reply. <i>Journal of Rheumatology</i> , 2017 , 44, 1565	4.1	
5	COVID-19 vaccination outcomes among patients with dermatomyositis: a multicentered analysis.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	
4	Evaluating the Patient with Suspected Myositis 2020 , 17-24		
3	Perioperative Management of the Patient with Idiopathic Inflammatory Myopathy 2013 , 201-208		
2	Response to: Elephant in the room by Hartung. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e12	2.4	
1	Telerheumatology and the Chronic Care Model 2022 , 209-226		